Liraglutide has been evaluated across numerous clinical trials ranging from early-stage through Phase IV development. Sponsored by academic institutions, biopharmaceutical companies, and major pharmaceutical manufacturers such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company, these studies encompass completed trials, active recruiting protocols, and post-marketing surveillance. Primary research targets metabolic disorders, including type 1 and type 2 diabetes mellitus and obesity, alongside exploratory indications such as knee osteoarthritis.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06742710 | RECRUITING | PCOS; Obesity; Infertility |
Peking University Third Hospital |
2025-05-22 | PHASE4 |
| NCT06976619 | RECRUITING | Type 1 Diabetes; Type 2 Diabetes |
Mayo Clinic |
2025-10-03 | PHASE2 |
| NCT05681299 | RECRUITING | Healthy; Growth Hormone Deficiency |
Columbia University |
2023-05-01 | PHASE4 |
| NCT07244003 | RECRUITING | T2DM (Type 2 Diabetes Mellitus) |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2025-03-29 | PHASE4 |
| NCT07301437 | NOT_YET_RECRUITING | Overweight and Obese Adults |
The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
2026-05-01 | PHASE4 |
| NCT06171152 | SUSPENDED | Multiple Sclerosis; Long COVID; Long Covid19; Obese; Obesity; Obesity, Morbid; Acute Leukemia in Remission |
University of Chicago |
2024-01-26 | EARLY_PHASE1 |
| NCT02944500 | ACTIVE_NOT_RECRUITING | Obesity |
Beth Israel Deaconess Medical Center |
2016-11 | PHASE4 |
| NCT03883412 | RECRUITING | Type2 Diabetes |
University of Virginia |
2019-02-28 | PHASE4 |
| NCT04575844 | RECRUITING | Metabolic Syndrome |
University of Virginia |
2020-11-01 | PHASE4 |
| NCT06836284 | RECRUITING | Childhood Obesity; Treatment Adherence |
Karolinska Institutet |
2026-02-13 | |
| NCT07590219 | ACTIVE_NOT_RECRUITING | Severe Obesity; Cardiovascular Function; Liraglutide; Childhood Obesity; Echocardiography; Speckle Tracking |
University of Sao Paulo General Hospital |
2024-03-30 | PHASE4 |
| NCT06361238 | RECRUITING | Delirium, Postoperative |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2024-11-19 | PHASE3 |
| NCT06865365 | NOT_YET_RECRUITING | Obesity, Adolescent |
Medical University of Vienna |
2025-05-01 | PHASE4 |
| NCT03856632 | ACTIVE_NOT_RECRUITING | Atrial Fibrillation |
University of Miami |
2019-03-18 | PHASE4 |
| NCT07225816 | RECRUITING | Obesity |
Novo Nordisk A/S |
2025-11-07 | PHASE1 |
| NCT07029009 | RECRUITING | Maturity Onset Diabetes of the Young |
Mansa |
2025-05-08 | PHASE2 |
| NCT05952882 | UNKNOWN | Polycystic Ovary Syndrome; Obesity; Infertility, Female |
Mỹ Đức Hospital |
2023-11-01 | PHASE3 |
| NCT05313529 | COMPLETED | Type 2 Diabetes Mellitus; Mild Cognitive Impairment |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2022-10-08 | |
| NCT06925334 | ENROLLING_BY_INVITATION | Type 2 Diabetic Patients |
Beijing Tsinghua Chang Gung Hospital |
2024-05-20 | PHASE4 |
| NCT05268237 | RECRUITING | Diabete Type 2 |
Biolingus |
2023-04-25 | PHASE1; PHASE2 |
| NCT05965908 | COMPLETED | Polycystic Ovary |
Beni-Suef University |
2024-08-01 | PHASE3 |
| NCT04683237 | WITHDRAWN | Atypical Endometrial Hyperplasia; Obese; Fertility Issues |
Xiaojun Chen |
2021-03-20 | PHASE2; PHASE3 |
| NCT06559722 | UNKNOWN | Type 2 Diabetes |
Tonghua Dongbao Pharmaceutical Co.,Ltd |
2024-08 | PHASE3 |
| NCT06439056 | COMPLETED | Type 2 Diabetes |
Nanexa AB |
2024-05-27 | PHASE1 |
| NCT07374445 | COMPLETED | Obesity; Weight Loss; Bariatric Surgery |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2023-09-01 | PHASE4 |
| NCT03011021 | UNKNOWN | Type1 Diabetes Mellitus; Autoimmune Diabetes |
Second Xiangya Hospital of Central South University |
2017-01 | PHASE1; PHASE2 |
| NCT06438146 | UNKNOWN | Obesity; HIV Infections |
Brigham and Women's Hospital |
2024-05-02 | PHASE4 |
| NCT05779644 | UNKNOWN | Metformin; Obesity, Abdominal; Diabetes Mellitus, Type 2; Abdominal Fat; Non-Alcoholic Fatty Liver Disease; Metabolism Disorder, Glucose; Metabolism Disorder, Lipid |
RenJi Hospital |
2023-02-23 | |
| NCT03087032 | RECRUITING | Type 2 Diabetes Patients; Overweight and Obesity; Hyperglycaemia (Diabetic) |
The First Affiliated Hospital of Xiamen University |
2019-01-10 | PHASE4 |
| NCT05705388 | UNKNOWN | Obesity |
Emirates Health Services (EHS) |
2023-01-16 | |
| NCT06400615 | COMPLETED | OSA |
Apnimed |
2024-05-20 | PHASE2 |
| NCT06818292 | COMPLETED | Healthy |
Nils Opel |
2024-10-21 | |
| NCT05579249 | COMPLETED | Obesity |
Novo Nordisk A/S |
2023-01-19 | PHASE4 |
| NCT06501326 | UNKNOWN | Non-alcoholic Fatty Liver Disease; Obesity |
Affiliated Hospital of Nantong University |
2023-11-01 | PHASE4 |
| NCT06500130 | COMPLETED | Gastroparesis; Functional Dyspepsia; Chronic Nausea and Vomiting Syndrome; Healthy |
Alimetry |
2024-05-30 | |
| NCT04324229 | ACTIVE_NOT_RECRUITING | Gestational Diabetes |
Turku University Hospital |
2020-02-07 | |
| NCT03260881 | COMPLETED | Type2 Diabetes; Coronary Artery Disease |
University of Miami |
2018-09-01 | PHASE4 |
| NCT03182426 | COMPLETED | Diabetes Mellitus, Type 1 |
University of Alberta |
2017-08-15 | PHASE1; PHASE2 |
| NCT06449703 | UNKNOWN | Healthy |
Tonghua Dongbao Pharmaceutical Co.,Ltd |
2024-05-06 | PHASE1 |
| NCT04883346 | COMPLETED | Obesity; Status Post Sleeve Gastrectomy |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
2021-06-21 | PHASE2 |
| NCT06283641 | Enrolling by invitation | Obesity |
Novo Nordisk A/S |
2024-02-23 | -- |
| NCT05390307 | COMPLETED | Type 1 Diabetes |
Dasman Diabetes Institute |
2023-04-01 | |
| NCT03948347 | UNKNOWN | Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus |
First Affiliated Hospital of Jinan University |
2019-06-25 | |
| NCT04763564 | TERMINATED | Pouchitis; Irritable Pouch Syndrome |
University of North Carolina, Chapel Hill |
2022-03-22 | PHASE2 |
| NCT02879409 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus Type 2 |
Weill Cornell Medical College in Qatar |
2016-11 | |
| NCT04535960 | UNKNOWN | Type 2 Diabetes Mellitus |
University Health Network, Toronto |
2019-01-24 | PHASE2 |
| NCT04199728 | COMPLETED | Opiate Substitution Treatment; Opioid-Related Disorders |
Milton S. Hershey Medical Center |
2021-10-18 | PHASE1; PHASE2 |
| NCT05767255 | UNKNOWN | Diabetes Mellitus, Type 2 Treated With Insulin |
Hospital Universitario San Ignacio |
2022-12-01 | PHASE3 |
| NCT04775082 | ACTIVE_NOT_RECRUITING | Obesity |
Novo Nordisk A/S |
2021-03-04 | PHASE3 |
| NCT05268237 | Recruiting | Diabete Type 2 |
Biolingus|Chinese University of Hong Kong |
2023-04-25 | Phase 1|Phase 2 |
| NCT06201819 | COMPLETED | Weight Loss; Bariatric Surgery Candidate; Obesity, Morbid |
Hospital Civil Juan I. Menchaca |
2022-12-18 | PHASE4 |
| NCT05467514 | COMPLETED | Diabetes Mellitus, Type 1 |
David Sanchez Garcia |
2022-07-01 | PHASE3 |
| NCT05444569 | COMPLETED | Healthy |
Eli Lilly and Company |
2022-08-08 | PHASE1 |
| NCT05268627 | UNKNOWN | Obesity |
Mansoura University |
2022-01-27 | |
| NCT04529278 | UNKNOWN | Diabetes Mellitus, Type 2; Hemodialysis; Obese |
Fondation Hôpital Saint-Joseph |
2021-01-18 | PHASE2 |
| NCT04881110 | COMPLETED | Type 2 Diabetes; Peripheral Arterial Disease |
University of Campania Luigi Vanvitelli |
2021-02-01 | PHASE4 |
| NCT04605861 | COMPLETED | Obese; Overweight |
Shanghai Zhongshan Hospital |
2020-08-18 | PHASE3 |
| NCT02344186 | UNKNOWN | Type 2 Diabetes |
Temple University |
2014-05 | PHASE4 |
| NCT04311411 | COMPLETED | Obesity; Overweight |
Eli Lilly and Company |
2020-08-24 | PHASE1 |
| NCT04137328 | UNKNOWN | Diabetic Neuropathic Pain |
Fudan University |
2019-11-30 | |
| NCT05111912 | COMPLETED | Obesity |
Sciwind Biosciences APAC CO Pty. Ltd. |
2021-11-30 | PHASE2 |
| NCT04657939 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Leeds |
2020-12-01 | PHASE4 |
| NCT03158805 | COMPLETED | Bipolar Disorder; Obesity |
Lindner Center of HOPE |
2017-04-26 | PHASE2 |
| NCT04575194 | UNKNOWN | Obesity; Blood Pressure |
National and Kapodistrian University of Athens |
2020-09-08 | PHASE4 |
| NCT03671733 | UNKNOWN | Obesity |
Xiangya Hospital of Central South University |
2018-09-01 | PHASE3 |
| NCT05285397 | UNKNOWN | Morbid Obesity |
General Committee of Teaching Hospitals and Institutes, Egypt |
2022-03-10 | |
| NCT04903509 | COMPLETED | Healthy |
Boehringer Ingelheim |
2021-06-08 | PHASE1 |
| NCT04531176 | TERMINATED | Type 2 Diabetes; Obesity |
The Cleveland Clinic |
2020-09-01 | PHASE4 |
| NCT02953665 | COMPLETED | Parkinson Disease |
Cedars-Sinai Medical Center |
2017-04-03 | PHASE2 |
| NCT02516657 | COMPLETED | Type 1 Diabetes |
University at Buffalo |
2012-05 | PHASE3 |
| NCT05419856 | Completed | Knee Osteoarthritis |
4Moving Biotech|4P-Pharma |
2022-08-09 | Phase 1 |
| NCT04057261 | WITHDRAWN | Type 2 Diabetes; Cardiovascular Diseases |
RWTH Aachen University |
2020-11 | PHASE3 |
| NCT04781998 | COMPLETED | Mental Disorder; Metabolic Disturbance; Feasibility; Overweight and Obesity; Liraglutide |
Anders Fink-Jensen, MD, DMSci |
2021-07-01 | PHASE4 |
| NCT05467514 | Completed | Diabetes Mellitus Type 1 |
David Sanchez Garcia|Instituto Mexicano del Seguro Social |
2022-07-01 | Phase 3 |
| NCT04487743 | UNKNOWN | Obesity |
Xiangya Hospital of Central South University |
2020-05-09 | PHASE3 |
| NCT04525300 | UNKNOWN | Obesity |
Xiangya Hospital of Central South University |
2020-05-24 | PHASE3 |
| NCT03374956 | COMPLETED | Obesity |
Mayo Clinic |
2017-12-11 | PHASE3 |
| NCT03712098 | COMPLETED | Smoking Cessation; Weight, Body |
Rebecca Ashare |
2018-11-29 | PHASE2 |
| NCT02960659 | COMPLETED | Type 2 Diabetes |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2017-05-09 | PHASE1; PHASE2 |
| NCT03795701 | COMPLETED | Obesity |
Texas Tech University |
2019-01-08 | |
| NCT04186494 | COMPLETED | Sleep Apnea, Obstructive |
St Vincent's University Hospital, Ireland |
2019-12-02 | |
| NCT04643301 | WITHDRAWN | Obesity; Obesity, Morbid |
Zuyderland Medisch Centrum |
2020-12-21 | |
| NCT04146155 | UNKNOWN | Type 2 Diabetes; Peripheral Vascular Disorder Due to Diabetes Mellitus |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2020-05-01 | PHASE4 |
| NCT03986008 | UNKNOWN | Obesity |
Xiangya Hospital of Central South University |
2019-12-01 | PHASE3 |
| NCT04373967 | UNKNOWN | Type 2 Diabetes |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-04-29 | PHASE3 |
| NCT05360537 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Palermo |
2021-04-01 | PHASE4 |
| NCT03632759 | COMPLETED | Type 1 Diabetes Mellitus |
Carla Greenbaum, MD |
2018-08-15 | EARLY_PHASE1 |
| NCT05041673 | UNKNOWN | Fatty Liver, Nonalcoholic; Diabetes Mellitus, Type 2 |
Alexandria University |
2021-02-23 | |
| NCT02920190 | WITHDRAWN | Monoclonal Gammopathies; Overweight; Obesity |
University of Miami |
2020-09-01 | PHASE4 |
| NCT03523273 | COMPLETED | Obesity |
Michael Camilleri, MD |
2017-11-29 | PHASE2 |
| NCT05225974 | COMPLETED | Therapeutic Equivalency |
The Affiliated Hospital of Qingdao University |
2021-07-16 | PHASE1 |
| NCT03101930 | COMPLETED | Obesity; PreDiabetes |
Vanderbilt University Medical Center |
2017-05-01 | PHASE4 |
| NCT02908087 | COMPLETED | Type 1 Diabetes |
University of Oulu |
2016-03 | PHASE2 |
| NCT01794143 | COMPLETED | Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications |
GRADE Study Group |
2013-05 | PHASE3 |
| NCT02403284 | COMPLETED | Insulin Resistance |
Phoenix VA Health Care System |
2013-03 | PHASE4 |
| NCT05360147 | COMPLETED | Type 2 Diabetes Mellitus |
Third Military Medical University |
2021-01-20 | PHASE3 |
| NCT03555994 | COMPLETED | Type 2 Diabetes Mellitus |
MedImmune LLC |
2018-05-31 | PHASE2 |
| NCT04008290 | UNKNOWN | Obesity |
Universitaire Ziekenhuizen KU Leuven |
2020-04-01 | PHASE4 |
| NCT04829903 | COMPLETED | Type 2 Diabetes Treated With Insulin; Obesity; Adolescent Obesity |
Corporacion Parc Tauli |
2020-01-02 | |
| NCT04074161 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2019-09-11 | PHASE3 |
| NCT03955575 | COMPLETED | Bile Acid Malabsorption |
Filip Krag Knop |
2019-03-07 | PHASE4 |
| NCT03048578 | COMPLETED | Obesity |
NYU Langone Health |
2017-05-22 | PHASE4 |
| NCT03036800 | COMPLETED | Obesity; Weight Loss; Diabetes Mellitus |
University of Leicester |
2017-11-28 | PHASE4 |
| NCT03480022 | COMPLETED | Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android |
Woman's |
2018-09-26 | PHASE3 |
| NCT04839237 | WITHDRAWN | Obesity |
Xiangya Hospital of Central South University |
2017-12-01 | PHASE2 |
| NCT03011008 | UNKNOWN | Type 1 Diabetes Mellitus; Autoimmune Diabetes |
Second Xiangya Hospital of Central South University |
2017-01 | PHASE4 |
| NCT02527200 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2015-11-09 | PHASE3 |
| NCT03038620 | COMPLETED | Obesity, Visceral; Cardiovascular Diseases; Fat Disorder |
University of Texas Southwestern Medical Center |
2017-01 | PHASE4 |
| NCT02617654 | COMPLETED | Type 1 Diabetes |
Per-Ola Carlsson |
2015-11 | PHASE2 |
| NCT01919489 | COMPLETED | Type 2 Diabetes |
Emory University |
2014-03 | PHASE4 |
| NCT03371862 | WITHDRAWN | Short Bowel Syndrome |
Imperial College London |
2017-10-20 | PHASE2 |
| NCT05294536 | COMPLETED | Type 2 Diabetes |
Sunshine Lake Pharma Co., Ltd. |
2020-06-22 | PHASE1 |
| NCT02198209 | WITHDRAWN | Type 2 Diabetes |
Cedars-Sinai Medical Center |
2019-12 | PHASE4 |
| NCT03500484 | TERMINATED | Obesity, Childhood; Neural Development |
Yale University |
2018-06-06 | EARLY_PHASE1 |
| NCT03466021 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Claus Bogh Juhl |
2018-01-01 | PHASE4 |
| NCT03426085 | UNKNOWN | Autonomic Nervous System Diseases; Sweat Gland Diseases; Diabetic Neuropathy With Neurologic Complication |
Eastern Virginia Medical School |
2016-05 | PHASE2 |
| NCT03347890 | COMPLETED | Obesity |
Zoltan Pataky |
2018-03-05 | PHASE4 |
| NCT03856047 | COMPLETED | Overweight; Obesity |
Novo Nordisk A/S |
2019-03-01 | PHASE2 |
| NCT03642600 | COMPLETED | PCOS; Obesity; Metabolic Syndrome |
Universitaire Ziekenhuizen KU Leuven |
2019-02-28 | PHASE4 |
| NCT04046822 | UNKNOWN | Obesity; Weight Loss; Microbiome |
Federico II University |
2019-01-09 | PHASE4 |
| NCT03757130 | COMPLETED | Obesity |
Amgen |
2018-11-26 | PHASE1 |
| NCT03672812 | COMPLETED | Brain Death |
Hospital de Clinicas de Porto Alegre |
2018-09-01 | PHASE3 |
| NCT03421119 | UNKNOWN | Diabetes Mellitus, Type 2 |
Cinnagen |
2019-06-20 | PHASE3 |
| NCT02655770 | COMPLETED | Diabetes Mellitus Type 2; Diastolic Dysfunction; Cardiac MRI; Myocardial Perfusion |
Rigshospitalet, Denmark |
2016-02 | PHASE4 |
| NCT01843075 | UNKNOWN | Alzheimer's Disease |
Imperial College London |
2014-01 | PHASE2 |
| NCT03341429 | COMPLETED | Obesity |
University College, London |
2018-08-22 | PHASE4 |
| NCT04190160 | COMPLETED | Type2 Diabetes |
Stefano Rizza |
2018-11-19 | |
| NCT02889510 | COMPLETED | Type 2 Diabetes |
Lecube, Albert, M.D. |
2016-10-04 | PHASE3 |
| NCT04122716 | UNKNOWN | Obesity |
Signe Torekov |
2016-09 | PHASE4 |
| NCT02721888 | TERMINATED | Type 2 Diabetes |
Centre Hospitalier Universitaire Dijon |
2012-07-10 | PHASE4 |
| NCT03279731 | TERMINATED | Binge-Eating Disorder |
Kelly Allison |
2017-09-29 | PHASE3 |
| NCT02650206 | COMPLETED | Diabetes Mellitus, Type 2; Diabetes Mellitus, Type II; Diabetes Mellitus, Adult-Onset; Inflammation |
Stanford University |
2015-01 | PHASE1 |
| NCT01795248 | COMPLETED | Gestational Diabetes Mellitus |
Tina Vilsboll |
2012-07 | PHASE4 |
| NCT03449654 | COMPLETED | Diabetes Mellitus, Type 2 |
Steno Diabetes Center Copenhagen |
2017-10-26 | PHASE4 |
| NCT02730377 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-03-28 | PHASE4 |
| NCT03172494 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-05-26 | PHASE3 |
| NCT05029076 | COMPLETED | Type 2 Diabetes |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-05-21 | PHASE1 |
| NCT03520062 | COMPLETED | Obesity |
Nicolai Jacob Wewer Albrechtsen |
2017-08-15 | |
| NCT01234649 | COMPLETED | Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus; Metabolic Syndrome; Impaired Glucose Tolerance; Disorder of Glucose Regulation |
Woman's |
2011-08-11 | PHASE3 |
| NCT03486392 | COMPLETED | Obesity |
Janssen Research & Development, LLC |
2018-03-26 | PHASE2 |
| NCT03175120 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-05-26 | PHASE3 |
| NCT02488057 | COMPLETED | Pre-Diabetes |
Ohio State University |
2016-05 | PHASE4 |
| NCT02765399 | COMPLETED | Type 2 Diabetes |
Helsinki University Central Hospital |
2015-02-01 | PHASE4 |
| NCT02928679 | COMPLETED | Osteoarthritis; Obesity |
Henrik Gudbergsen |
2016-11 | PHASE4 |
| NCT02918279 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2016-09-29 | PHASE3 |
| NCT03707171 | COMPLETED | Type 2 Diabetes Mellitus |
Third Military Medical University |
2018-10-01 | PHASE3 |
| NCT02910570 | COMPLETED | Osteoarthritis, Knee |
Parker Research Institute |
2016-11 | PHASE4 |
| NCT01779362 | COMPLETED | Prediabetes; Type 2 Diabetes |
RISE Study Group |
2013-04 | PHASE3 |
| NCT02931383 | COMPLETED | Osteoarthritis; Obesity |
Henrik Gudbergsen |
2016-11 | PHASE4 |
| NCT02928614 | COMPLETED | Osteoarthritis; Obesity |
Henrik Gudbergsen |
2016-11 | PHASE4 |
| NCT02905864 | COMPLETED | Osteoarthritis; Obesity |
Henrik Gudbergsen |
2016-11 | PHASE4 |
| NCT01722240 | COMPLETED | Type 1 Diabetes |
University at Buffalo |
2012-11-01 | PHASE3 |
| NCT04325581 | COMPLETED | Weight Loss |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2016-08-01 | PHASE3 |
| NCT02535299 | UNKNOWN | GLP-1;Metformin;Telomere-telomerase System;Par-4 |
Third Military Medical University |
2016-06 | PHASE4 |
| NCT02911818 | COMPLETED | Obesity |
University of Pennsylvania |
2016-09 | PHASE4 |
| NCT02501161 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-01-31 | PHASE3 |
| NCT02963922 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2017-02-06 | PHASE3 |
| NCT02443155 | COMPLETED | Diabetes; Diabetes Mellitus, Type 1 |
Novo Nordisk A/S |
2015-11-10 | PHASE2 |
| NCT01879917 | COMPLETED | Diabetes Mellitus, Type 1 |
Hvidovre University Hospital |
2014-02 | PHASE2; PHASE3 |
| NCT02231658 | TERMINATED | Diabetes Mellitus |
Profil Institut für Stoffwechselforschung GmbH |
2015-07-16 | PHASE1 |
| NCT03191396 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-06-27 | PHASE3 |
| NCT02743598 | TERMINATED | HIV Infection; Diabetes Mellitus Type 2; Obesity; Overweight; Metabolic Syndrome |
Temple University |
2016-09 | PHASE4 |
| NCT02787551 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2016-07-06 | PHASE3 |
| NCT02963935 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2017-02-06 | PHASE3 |
| NCT02964247 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-03-03 | PHASE3 |
| NCT03235050 | COMPLETED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2017-08-02 | PHASE2 |
| NCT03115099 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2017-05-31 | PHASE1 |
| NCT02324842 | COMPLETED | Type 2 Diabetes Mellitus |
The University of Texas Health Science Center at San Antonio |
2014-11 | |
| NCT02660047 | COMPLETED | Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver |
Leiden University Medical Center |
2015-08 | PHASE4 |
| NCT02060383 | COMPLETED | Cushing's Disease; Acromegaly |
Novartis Pharmaceuticals |
2014-05-23 | PHASE4 |
| NCT02650596 | UNKNOWN | Heart Failure |
Shi Yang |
2016-01 | |
| NCT02930265 | UNKNOWN | Ischemic Cardiomyopathy |
Chinese PLA General Hospital |
2016-09 | |
| NCT03041792 | COMPLETED | Obesity |
Pfizer |
2017-02-20 | PHASE1 |
| NCT03018028 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-01-10 | PHASE3 |
| NCT03292185 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-09-29 | PHASE1 |
| NCT02616003 | COMPLETED | Morbid Obesity; Bariatric Surgery Candidate |
Sana Klinikum Offenbach |
2014-04 | PHASE4 |
| NCT02973321 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2016-12-02 | PHASE2 |
| NCT02607306 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2015-11-18 | PHASE3 |
| NCT01753362 | COMPLETED | Type 1 Diabetes |
University at Buffalo |
2012-12 | PHASE3 |
| NCT01966978 | COMPLETED | Diabetes Mellitus, Type 2; Diabetes |
University of Texas Southwestern Medical Center |
2014-11 | PHASE4 |
| NCT02654665 | UNKNOWN | Non-alcoholic Fatty Liver Disease (NAFLD); Weight Loss; Non-alcoholic Steatohepatitis (NASH) |
Changi General Hospital |
2014-03 | PHASE3 |
| NCT02911948 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-09-21 | PHASE3 |
| NCT01541215 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2012-11-13 | PHASE3 |
| NCT01722227 | WITHDRAWN | Type 1 Diabetes |
University at Buffalo |
2012-11 | PHASE3 |
| NCT02473809 | COMPLETED | Diabetes Complications; Osteoporosis |
University of Aarhus |
2015-08 | PHASE4 |
| NCT02638805 | COMPLETED | Diabetes Mellitus, Type 2 |
Intarcia Therapeutics |
2015-12 | PHASE3 |
| NCT02773368 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-05-23 | PHASE3 |
| NCT01232946 | COMPLETED | Type 2 Diabetes |
Indiana University |
2012-01 | |
| NCT02870231 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2016-08-18 | PHASE1 |
| NCT02043054 | COMPLETED | Type 2 Diabetes Mellitus; Cardiovascular Disease |
University of Leicester |
2013-12-16 | PHASE3 |
| NCT02863419 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-08-10 | PHASE3 |
| NCT02686177 | COMPLETED | Type 2 Diabetes |
Assistance Publique - Hôpitaux de Paris |
2016-05-18 | PHASE4 |
| NCT03010683 | COMPLETED | Type 2 Diabetes Mellitus; Coronary Artery Disease |
University of Athens |
2015-11 | |
| NCT02505334 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2015-07-21 | PHASE3 |
| NCT02492763 | TERMINATED | Type II Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2015-07-27 | PHASE2 |
| NCT02602600 | COMPLETED | Microvascular Angina |
Eva Prescott |
2015-11-19 | PHASE4 |
| NCT02696148 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2016-03-14 | PHASE1 |
| NCT02527993 | COMPLETED | Hypoglycemia; Obesity; Surgery |
Zealand University Hospital |
2015-10 | PHASE4 |
| NCT02147925 | COMPLETED | Non-alcoholic Fatty Liver Disease |
Sun Yat-sen University |
2014-08 | PHASE4 |
| NCT02453711 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2015-10-01 | PHASE2 |
| NCT02718950 | UNKNOWN | Obesity; Type 2 Diabetes Mellitus |
University of Campinas, Brazil |
2016-06 | PHASE3 |
| NCT02014740 | COMPLETED | Type 2 Diabetes; Overweight; Obesity |
University of Miami |
2014-03 | PHASE4 |
| NCT02055014 | UNKNOWN | Type 2 Diabetes; Obesity; Diabesity |
Sandwell & West Birmingham Hospitals NHS Trust |
2013-07 | PHASE4 |
| NCT02717858 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2016-03-16 | PHASE1 |
| NCT02138045 | COMPLETED | Diabetes Mellitus, Type 1; Type 1 Diabetes Mellitus |
Aalborg University Hospital |
2014-05 | |
| NCT02140983 | COMPLETED | Insulin Resistance; Dementia |
Stanford University |
2013-08 | PHASE1 |
| NCT03534310 | COMPLETED | Obesity |
Catholic University of the Sacred Heart |
2015-11-02 | |
| NCT02036372 | COMPLETED | Diabetes Mellitus Type II |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2014-01 | |
| NCT02647944 | COMPLETED | Obesity |
Mayo Clinic |
2015-12-18 | PHASE2 |
| NCT02777073 | COMPLETED | Type 1 Diabetes |
University at Buffalo |
2016-03-01 | |
| NCT02783196 | UNKNOWN | Type 2 Diabetes |
Tel Aviv University |
2016-07 | |
| NCT03034941 | COMPLETED | Obesity; PCOS |
University Medical Centre Ljubljana |
2014-04 | PHASE4 |
| NCT02299388 | COMPLETED | Diabetes Mellitus, Non-Insulin-Dependent; Hypertensive Disease |
Tulane University School of Medicine |
2014-10 | PHASE4 |
| NCT02461589 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2015-09-21 | PHASE2 |
| NCT02420262 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2015-07-26 | PHASE3 |
| NCT02577848 | UNKNOWN | Myocardial Infarction |
Chinese PLA General Hospital |
2015-10 | |
| NCT02472717 | WITHDRAWN | Psoriatic Arthritis; Psoriasis; Impaired Glucose Tolerance; Type 2 Diabetes |
University Health Network, Toronto |
2015-05 | PHASE2 |
| NCT02351232 | COMPLETED | Type 1 Diabetes |
Hvidovre University Hospital |
2015-02 | PHASE2; PHASE3 |
| NCT02417103 | TERMINATED | Obesity |
Universitätsklinikum Hamburg-Eppendorf |
2011-12 | PHASE3 |
| NCT02503943 | UNKNOWN | Type 2 Diabetes; Overweight; Obesity; Masked Hypertension |
Third Affiliated Hospital of Third Military Medical University |
2015-05 | PHASE4 |
| NCT02832999 | COMPLETED | Type 2 Diabetes Mellitus |
Yaounde Central Hospital |
2016-01 | PHASE4 |
| NCT02674893 | TERMINATED | Type 2 Diabetes; Overweight |
Centre Hospitalier Universitaire Dijon |
2014-02-04 | PHASE4 |
| NCT01425580 | COMPLETED | Congestive Heart Failure; Type 2 Diabetes Mellitus |
Thomas Nystrom |
2012-01 | PHASE2 |
| NCT02235961 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2014-09-04 | PHASE1 |
| NCT02490176 | UNKNOWN | Heart Failure |
Chinese PLA General Hospital |
2015-07 | |
| NCT02507128 | UNKNOWN | Acute ST-segment Elevation Myocardial Infarction |
Chen Wei Ren, MD |
2015-07 | |
| NCT01505673 | COMPLETED | Type 2 Diabetes Mellitus; Obesity |
Ildiko Lingvay |
2012-01 | PHASE4 |
| NCT03353948 | COMPLETED | Polycystic Ovary Syndrome; Obesity; Infertility, Female |
University Medical Centre Ljubljana |
2014-09-01 | PHASE4 |
| NCT02545738 | COMPLETED | Diabetic Kidney Disease |
Steno Diabetes Center Copenhagen |
2015-04 | PHASE4 |
| NCT02408705 | COMPLETED | Type 1 Diabetes Mellitus |
Medical University of Graz |
2015-01 | PHASE2 |
| NCT02082496 | COMPLETED | Obesity |
University of Copenhagen |
2014-06 | PHASE2 |
| NCT02423824 | COMPLETED | Bipolar Disorder; Major Depressive Disorder |
University Health Network, Toronto |
2015-05 | PHASE3 |
| NCT02001363 | UNKNOWN | Acute Myocardial Infarction |
Chen Wei Ren, MD |
2013-11 | |
| NCT01845259 | UNKNOWN | Impaired Glucose Tolerance Associated With Drugs |
Psychiatric Centre Rigshospitalet |
2013-04 | PHASE2 |
| NCT01761318 | COMPLETED | Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver |
Leiden University Medical Center |
2013-11 | PHASE4 |
| NCT02298192 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2014-11-21 | PHASE3 |
| NCT01179048 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2010-08-31 | PHASE3 |
| NCT02073929 | COMPLETED | Polycystic Ovary Syndrome; Cardiovascular Disease |
Jens Faber |
2014-03 | PHASE4 |
| NCT02518945 | COMPLETED | Type 1 Diabetes Mellitus |
University at Buffalo |
2015-08 | PHASE3 |
| NCT01740921 | COMPLETED | Type 2 Diabetes |
Royal Devon and Exeter NHS Foundation Trust |
2011-01 | |
| NCT01832532 | COMPLETED | Sleep Apnea; Sleep Disordered Breathing |
Children's Hospital Medical Center, Cincinnati |
2013-04 | PHASE1; PHASE2 |
| NCT01847313 | COMPLETED | Diabetic Kidney Disease |
Karl Neff |
2013-04 | PHASE3 |
| NCT02584582 | UNKNOWN | Type 1 Diabetes |
Hvidovre University Hospital |
2015-07 | PHASE2; PHASE3 |
| NCT01628445 | TERMINATED | Type 2 Diabetes |
University of Manitoba |
2012-08 | PHASE3 |
| NCT01856790 | COMPLETED | Type 1 Diabetes |
Jennifer Sherr |
2013-02 | EARLY_PHASE1 |
| NCT02072096 | TERMINATED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2014-02 | PHASE4 |
| NCT02909933 | COMPLETED | Polycystic Ovary Syndrome; Obesity |
University Medical Centre Ljubljana |
2015-07 | PHASE4 |
| NCT01800968 | COMPLETED | Acute Heart Failure |
Duke University |
2013-04 | PHASE2 |
| NCT02205528 | COMPLETED | Diabetes; Diabetes Mellitus Type 2 |
Novo Nordisk A/S |
2014-08-18 | PHASE2 |
| NCT01472640 | COMPLETED | Hyperglycemia; Chronic Heart Failure |
Flyvbjerg, Allan, DMSc |
2011-11 | |
| NCT01744236 | COMPLETED | Type 2 Diabetes |
Amsterdam UMC, location VUmc |
2013-04 | PHASE4 |
| NCT02284230 | WITHDRAWN | Kidney Failure, Chronic; Prediabetic State |
Bo Feldt-Rasmussen |
2014-12 | PHASE2 |
| NCT03619330 | COMPLETED | Hypogonadism; Obesity |
University Medical Centre Ljubljana |
2014-12 | PHASE4 |
| NCT02501850 | UNKNOWN | Diabetes Mellitus Type 2 |
Hospital Universitari Vall d'Hebron Research Institute |
2014-10 | PHASE4 |
| NCT01575301 | COMPLETED | Diabetes |
University of Dundee |
2011-03 | |
| NCT01907854 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2013-12-02 | PHASE4 |
| NCT01836523 | COMPLETED | Diabetes; Diabetes Mellitus, Type 1 |
Novo Nordisk A/S |
2013-11 | PHASE3 |
| NCT02109315 | WITHDRAWN | Type 1 Diabetes Mellitus |
Anna Cruceta |
2014-05 | PHASE1 |
| NCT02098395 | COMPLETED | Diabetes; Diabetes Mellitus, Type 1 |
Novo Nordisk A/S |
2014-05 | PHASE3 |
| NCT01787916 | COMPLETED | Type 1 Diabetes |
CHU de Quebec-Universite Laval |
2013-04 | PHASE4 |
| NCT02100475 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2014-04 | PHASE3 |
| NCT02483299 | COMPLETED | PCOS; Obesity |
University Medical Centre Ljubljana |
2014-01 | PHASE4 |
| NCT02089256 | COMPLETED | Healthy |
University of Tartu |
2014-06 | PHASE4 |
| NCT02315001 | COMPLETED | Ischaemic Heart Disease; Coronary Heart Disease; Chronic Stable Angina |
King's College London |
2014-01 | PHASE2 |
| NCT01612468 | COMPLETED | Diabetes Mellitus, Type 1; Overweight |
Steno Diabetes Center Copenhagen |
2012-06 | PHASE4 |
| NCT01782261 | COMPLETED | Type 1 Diabetes |
Medical University of Graz |
2012-02 | PHASE2 |
| NCT02016846 | UNKNOWN | Glucocorticoid Induced Hyperglycemia |
Rabin Medical Center |
2014-01 | PHASE3 |
| NCT01755416 | COMPLETED | Type 1 Diabetes |
Albert Einstein College of Medicine |
2013-01 | PHASE2 |
| NCT01363609 | COMPLETED | Obesity; Type 2 Diabetes |
Amsterdam UMC, location VUmc |
2011-10 | |
| NCT01870297 | COMPLETED | Type 2 Diabetes Mellitus |
Eli Lilly and Company |
2013-06 | PHASE1 |
| NCT01790308 | UNKNOWN | Diabetes Mellitus, Type 2 |
Sun Yat-sen University |
2013-02 | PHASE4 |
| NCT01952145 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2013-09-20 | PHASE3 |
| NCT03068065 | COMPLETED | Non-Alcoholic Fatty Liver Disease; Type2 Diabetes |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2014-05 | PHASE4 |
| NCT01973231 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2013-10 | PHASE4 |
| NCT02008682 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2013-12 | PHASE4 |
| NCT01982630 | COMPLETED | Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2013-11-07 | PHASE1 |
| NCT01595789 | COMPLETED | Coronary Artery Disease; Diabetes Mellitus, Type 2 |
Haugaard, Steen Bendix, M.D., DMSc |
2012-05 | PHASE4 |
| NCT02057172 | COMPLETED | Type 2 Diabetes |
Hanmi Pharmaceutical Company Limited |
2014-01 | PHASE2 |
| NCT02092896 | COMPLETED | Diabetes; Diabetes Mellitus, Type 1 |
Hvidovre University Hospital |
2013-03 | PHASE3 |
| NCT01954147 | UNKNOWN | Type 2 Diabetes |
Diabetes Care Center of Nanjing Military Command |
2013-10 | PHASE1; PHASE2 |
| NCT01917656 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2014-01-09 | PHASE4 |
| NCT02207348 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2014-08 | PHASE1 |
| NCT02113332 | COMPLETED | Type 2 Diabetes Mellitus |
Vastra Gotaland Region |
2013-01 | PHASE2 |
| NCT01237119 | COMPLETED | Nonalcoholic Steatohepatitis |
University of Birmingham |
2010-08 | PHASE2 |
| NCT01399645 | COMPLETED | Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes |
Centre hospitalier de l'Université de Montréal (CHUM) |
2011-05 | PHASE2 |
| NCT01592279 | UNKNOWN | Uncontrolled Type 1 Diabetic Patients |
Hadassah Medical Organization |
2012-06 | PHASE4 |
| NCT02187250 | COMPLETED | PCOS; Obesity |
University Medical Centre Ljubljana |
2014-03 | PHASE4 |
| NCT01597531 | TERMINATED | Type 2 Diabetes; Gastric Banding |
East Carolina University |
2012-06 | PHASE4 |
| NCT01733758 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2013-02 | PHASE3 |
| NCT01562678 | COMPLETED | Diabetes; Effects of Liraglutide Administration on Brain Activity; Weight Loss; Hunger |
Beth Israel Deaconess Medical Center |
2012-03 | PHASE4 |
| NCT01392898 | UNKNOWN | Type 2 Diabetes Mellitus |
Radboud University Medical Center |
2012-02 | |
| NCT01789086 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2013-02 | PHASE1 |
| NCT01722266 | COMPLETED | Type 1 Diabetes |
University at Buffalo |
2012-11-01 | PHASE3 |
| NCT01937598 | COMPLETED | Type 2 Diabetes |
Michael A. Nauck |
2013-08 | PHASE3 |
| NCT01676116 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2012-08-29 | PHASE3 |
| NCT01785043 | COMPLETED | DIABETES Mellitus Type 2 Not Well Controlled |
Anna Cruceta |
2013-03 | PHASE4 |
| NCT01664676 | COMPLETED | Type 2 Diabetes Mellitus |
University of Aarhus |
2012-12 | PHASE4 |
| NCT01755572 | COMPLETED | Type 2 Diabetes; Systolic Hypertension |
Mount Sinai Hospital, Canada |
2013-01 | PHASE4 |
| NCT01664247 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2012-10-01 | PHASE3 |
| NCT02104037 | COMPLETED | Liraglutide Blood-brain Transfer |
Mikkel Christensen |
2012-01 | |
| NCT01550653 | COMPLETED | Healthy |
University of Luebeck |
2012-05 | PHASE1 |
| NCT01593137 | WITHDRAWN | Type 2 Diabetes |
Fundación Fernández-Cruz |
2012-05 | PHASE4 |
| NCT01270789 | COMPLETED | Type 2 Diabetes |
Mount Sinai Hospital, Canada |
2011-01 | PHASE3 |
| NCT01654120 | COMPLETED | Diabetes Mellitus, Type II |
Mountain Diabetes and Endocrine Center |
2011-12 | PHASE4 |
| NCT01624259 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2012-06 | PHASE3 |
| NCT01916174 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2013-08 | PHASE1 |
| NCT01638260 | TERMINATED | Type 2 Diabetes Mellitus |
Maastricht University Medical Center |
2012-10 | PHASE4 |
| NCT01618162 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2012-08-29 | PHASE3 |
| NCT01394341 | COMPLETED | Type 2 Diabetes Mellitus; End-stage Renal Disease |
Bo Feldt-Rasmussen |
2011-09 | PHASE4 |
| NCT01739049 | COMPLETED | Binge Eating Behaviour |
Universiti Kebangsaan Malaysia Medical Centre |
2012-11 | PHASE4 |
| NCT01617434 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2012-09 | PHASE3 |
| NCT01558271 | COMPLETED | Type 2 Diabetes Mellitus |
Eli Lilly and Company |
2012-03 | PHASE3 |
| NCT01725126 | COMPLETED | Obesity |
GlaxoSmithKline |
2013-02-10 | PHASE2 |
| NCT01620489 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2012-06-14 | PHASE3 |
| NCT01610934 | COMPLETED | Maturity-onset Diabetes of the Young |
University Hospital, Gentofte, Copenhagen |
2012-08 | PHASE2; PHASE3 |
| NCT01596504 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2012-05 | PHASE2 |
| NCT01499108 | COMPLETED | Type 2 Diabetes |
Peter Rossing |
2012-08 | PHASE4 |
| NCT01206101 | TERMINATED | Diabetes; Diabetes Mellitus, Type 1 |
Novo Nordisk A/S |
2012-03-21 | PHASE2 |
| NCT01557166 | COMPLETED | Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea |
Novo Nordisk A/S |
2012-06-07 | PHASE3 |
| NCT01455441 | COMPLETED | Type 2 Diabetes |
Tina Vilsboll |
2011-10 | PHASE4 |
| NCT01460069 | COMPLETED | Psoriasis |
Annesofie Faurschou |
2011-10 | |
| NCT01512108 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2012-01-10 | PHASE3 |
| NCT01469351 | COMPLETED | Alzheimers Disease |
University of Aarhus |
2012-01 | |
| NCT01272219 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2011-06-01 | PHASE3 |
| NCT01542242 | TERMINATED | Diabetes Mellitus Type 2; Prader Willi Syndrome |
Vancouver General Hospital |
2012-02 | PHASE4 |
| NCT01272232 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2011-06-01 | PHASE3 |
| NCT01784965 | COMPLETED | Pre-diabetes; Older Adults |
Stanford University |
2009-12 | PHASE3 |
| NCT02292290 | COMPLETED | Type 2 Diabetes |
University of Leicester |
2011-04 | PHASE4 |
| NCT01451905 | UNKNOWN | Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI |
University Hospital, Gentofte, Copenhagen |
2011-08 | |
| NCT01572740 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2012-04-05 | PHASE3 |
| NCT01392573 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2011-11-28 | PHASE3 |
| NCT01899430 | COMPLETED | PCOS; Obesity |
University Medical Centre Ljubljana |
2011-11 | PHASE4 |
| NCT01911468 | COMPLETED | PCOS; Obesity |
University Medical Centre Ljubljana |
2011-11 | PHASE4 |
| NCT01117350 | COMPLETED | Diabetes Mellitus, Type 2 |
Sanofi |
2010-07 | PHASE4 |
| NCT01518101 | COMPLETED | Type 2 Diabetes |
Novartis Pharmaceuticals |
2012-01 | PHASE4 |
| NCT01536665 | COMPLETED | Diabetes; Diabetes Mellitus, Type 1 |
Novo Nordisk A/S |
2012-02 | PHASE1 |
| NCT01388361 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2011-09 | PHASE3 |
| NCT01336023 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2011-05-23 | PHASE3 |
| NCT01473953 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2011-10 | PHASE1 |
| NCT01296412 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2011-03-11 | PHASE3 |
| NCT01695109 | COMPLETED | Healthy Human Male Subjects |
Medical University of Vienna |
2010-11 | PHASE4 |
| NCT01516476 | TERMINATED | Diabetes Mellitus Type 2 |
Hoffmann-La Roche |
2011-11 | PHASE2 |
| NCT00943501 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2009-11 | PHASE1 |
| NCT01128894 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2010-05 | PHASE3 |
| NCT01373450 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2011-06 | PHASE1 |
| NCT00978393 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2009-09-16 | PHASE1 |
| NCT01319240 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2011-03 | PHASE1 |
| NCT01029886 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2010-01 | PHASE3 |
| NCT01599338 | COMPLETED | Type 2 Diabetes Mellitus; Overweight |
Centre Hospitalier Universitaire Dijon |
2011-01 | |
| NCT00993304 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2009-10 | PHASE1 |
| NCT01175473 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2010-08 | PHASE2 |
| NCT01208012 | COMPLETED | Diabetes Mellitus, Type 2 |
ikfe-CRO GmbH |
2010-04 | PHASE4 |
| NCT00993720 | COMPLETED | Diabetes Mellitus |
Hvidovre University Hospital |
2009-10 | PHASE2; PHASE3 |
| NCT00781937 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2008-10-30 | PHASE3 |
| NCT00620282 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2008-02 | PHASE3 |
| NCT00856986 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2009-03 | PHASE3 |
| NCT00983021 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2009-09 | PHASE1 |
| NCT00873223 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2009-03 | PHASE1 |
| NCT00700817 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2008-06 | PHASE3 |
| NCT00696657 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2008-06-03 | PHASE2 |
| NCT00614120 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2008-01 | PHASE3 |
| NCT00761540 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2008-10 | PHASE1 |
| NCT00294723 | TERMINATED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-02 | PHASE3 |
| NCT00518882 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2007-08 | PHASE3 |
| NCT00393718 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-11 | PHASE3 |
| NCT00395746 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-10 | PHASE3 |
| NCT00422058 | COMPLETED | Metabolism and Nutrition Disorder; Obesity |
Novo Nordisk A/S |
2007-01-10 | PHASE2 |
| NCT01511692 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2005-11 | PHASE1 |
| NCT00333151 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-05 | PHASE3 |
| NCT01513525 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2007-02 | PHASE1 |
| NCT01517555 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-10 | PHASE1 |
| NCT00318461 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-05 | PHASE3 |
| NCT00318422 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-05 | PHASE3 |
| NCT01515553 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2007-01 | PHASE1 |
| NCT01508858 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-11 | PHASE1 |
| NCT01518166 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2006-05 | PHASE1 |
| NCT00331851 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-05 | PHASE3 |
| NCT01517568 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2006-11 | PHASE1 |
| NCT01516255 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-07 | PHASE1 |
| NCT01507389 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-03 | PHASE1 |
| NCT01515579 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2006-04 | PHASE1 |
| NCT00154414 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2005-01 | PHASE2 |
| NCT01515592 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-01 | PHASE1 |
| NCT01508806 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2005-08 | PHASE1 |
| NCT00154401 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2005-01 | PHASE2 |
| NCT01514487 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2005-01-13 | PHASE1 |
| NCT01508897 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2004-05-28 | PHASE1 |
| NCT01507337 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2004-04 | PHASE1 |
| NCT01620476 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2003-09 | PHASE1 |
| NCT01615978 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2003-12 | PHASE1 |
| NCT01620463 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2002-12 | PHASE1 |
| NCT01511172 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2002-08 | PHASE2 |
| NCT01508949 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2001-06 | PHASE2 |
| NCT01508923 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2001-05 | PHASE2 |
| NCT01511159 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2001-10 | PHASE1 |
| NCT01509742 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2001-04 | PHASE1 |
| NCT01511198 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2001-02 | PHASE2 |
| NCT01509755 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2000-10 | PHASE2 |
| NCT01511185 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2001-02 | PHASE1 |
| NCT01507311 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
1999-09 | PHASE1 |
| NCT01507272 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
1999-03 | PHASE1 |
| NCT01507285 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
1999-08 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2025-05-29)
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).